Evidence map›Paper›PMID 19491105›Full record

ArticleThe Journal of biological chemistry2009

Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein.

Sanae Nakayama, Takayuki Murata, Kazutaka Murayama, Yoshihiro Yasui, Yoshitaka Sato, Ayumi Kudoh, Satoko Iwahori, Hiroki Isomura, Teru Kanda, Tatsuya Tsurumi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Replication of Epstein-Barr viral DNA.Cold Spring Harbor perspectives in biology · 2013
    Review
  12. Epstein-Barr virus and systemic lupus erythematosus.Clinical & developmental immunology · 2012
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sanae NakayamaDivision of Virology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan.
Takayuki Murata
Kazutaka Murayama
Yoshihiro Yasui
Yoshitaka Sato
Ayumi Kudoh
Satoko Iwahori
Hiroki Isomura
Teru Kanda
Tatsuya Tsurumi
Aichi Cancer Center · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Epstein-Barr virus (EBV) BMRF1 protein is an essential replication protein acting at viral replication forks as a viral DNA polymerase processivity factor, whereas the BALF2 protein is a single-stranded DNA-binding protein that also acts at replication forks and is most abundantly expressed during viral productive replication. Here we document that the BMRF1 protein evidently enhances viral BZLF1 transcription factor-mediated transactivation of the BALF2 gene promoter. Mutagenesis and electrophoretic mobility shift assays demonstrated the BALF2 promoter to harbor two BZLF1 protein-binding sites (BZLF1-responsive elements). Direct binding of the BZLF1 protein to BZLF1-responsive elements and physical interaction between BZLF1 and BMRF1 proteins are prerequisite for the BMRF1 protein up-regulation of the BALF2 gene promoter. A monomeric mutant, C95E, which is defective in homodimerization, could still interact and enhance BZLF1-mediated transactivation. Furthermore although EBV protein kinase phosphorylates BMRF1 protein extensively, it turned out that phosphorylation of the protein by the kinase is inhibitory to the enhancement of the BZLF1-mediated transactivation of BALF2 promoter. Exogenous expression of BMRF1 protein augmented BALF2 expression in HEK293 cells harboring the EBV genome but lacking BMRF1 and BALF5 genes, demonstrating functions as a transcriptional regulator in the context of viral infection. Overall the BMRF1 protein is a multifunctional protein that cannot only act as a DNA polymerase processivity factor but also enhances BALF2 promoter transcription as a coactivator for the BZLF1 protein, regulating the expression level of viral single-stranded DNA-binding protein.

Indexed as

Gene Expression Regulation, ViralAntigens, ViralBase SequenceBinding, CompetitiveCell Line, TumorDNA-Binding ProteinsDNA Mutational AnalysisHerpesvirus 4, HumanHumansLuciferasesModels, BiologicalMolecular Sequence DataPromoter Regions, GeneticRecombinant ProteinsTrans-ActivatorsViral ProteinsAntigens, ViralBALF2 protein, Human herpesvirus 4BZLF1 protein, Herpesvirus 4, HumanDNA-Binding ProteinsEpstein-Barr virus early antigen diffuse componentLuciferasesRecombinant ProteinsTrans-ActivatorsViral Proteins

Identifiers

PMID19491105
PMCPMC2755880
OpenAlexW1984340438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.